Oh WK - Search Results

1

Genome-wide association study of prostate cancer mortality.

Penney KL, Pyne S, Schumacher FR, Sinnott JA, Mucci LA, Kraft PL, Ma J, Oh WK, Kurth T, Kantoff PW, Giovannucci EL, Stampfer MJ, Hunter DJ, Freedman ML. Penney KL, et al. Among authors: oh wk. Cancer Epidemiol Biomarkers Prev. 2010 Nov;19(11):2869-76. doi: 10.1158/1055-9965.EPI-10-0601. Epub 2010 Oct 26. Cancer Epidemiol Biomarkers Prev. 2010. PMID: 20978177 Free PMC article.

2

Management of hormone refractory prostate cancer: current standards and future prospects.

Oh WK, Kantoff PW. Oh WK, et al. J Urol. 1998 Oct;160(4):1220-9. J Urol. 1998. PMID: 9751323 Review.

3

A phase II trial of methotrexate, cisplatin, 5-fluorouracil, and leucovorin in the treatment of invasive and metastatic urothelial carcinoma.

Oh WK, Manola J, Richie JP, Loughlin KR, Kantoff PW. Oh WK, et al. Cancer. 1999 Oct 1;86(7):1329-34. doi: 10.1002/(sici)1097-0142(19991001)86:7<1329::aid-cncr31>3.0.co;2-r. Cancer. 1999. PMID: 10506721 Clinical Trial.

4

Treatment of locally advanced prostate cancer: is chemotherapy the next step?

Oh WK, Kantoff PW. Oh WK, et al. J Clin Oncol. 1999 Nov;17(11):3664-75. doi: 10.1200/JCO.1999.17.11.3664. J Clin Oncol. 1999. PMID: 10550165 Review.

5

Docetaxel (Taxotere)-based chemotherapy for hormone-refractory and locally advanced prostate cancer.

Oh WK, Kantoff PW. Oh WK, et al. Semin Oncol. 1999 Oct;26(5 Suppl 17):49-54. Semin Oncol. 1999. PMID: 10604270 Review.

6

Smoking and alcohol use may be risk factors for poorer outcome in patients with clear cell renal carcinoma.

Oh WK, Manola J, Renshaw AA, Brodkin D, Loughlin KR, Richie JP, Shapiro CL, Kantoff PW. Oh WK, et al. Urology. 2000 Jan;55(1):31-5. doi: 10.1016/s0090-4295(99)00408-2. Urology. 2000. PMID: 10654890

7

Antiandrogens in prostate cancer.

Reid P, Kantoff P, Oh W. Reid P, et al. Invest New Drugs. 1999;17(3):271-84. doi: 10.1023/a:1006344807086. Invest New Drugs. 1999. PMID: 10665479 Review.

8

A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer.

Eder JP, Kantoff PW, Roper K, Xu GX, Bubley GJ, Boyden J, Gritz L, Mazzara G, Oh WK, Arlen P, Tsang KY, Panicali D, Schlom J, Kufe DW. Eder JP, et al. Among authors: oh wk. Clin Cancer Res. 2000 May;6(5):1632-8. Clin Cancer Res. 2000. PMID: 10815880 Clinical Trial.

9

Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer.

Mueller E, Smith M, Sarraf P, Kroll T, Aiyer A, Kaufman DS, Oh W, Demetri G, Figg WD, Zhou XP, Eng C, Spiegelman BM, Kantoff PW. Mueller E, et al. Proc Natl Acad Sci U S A. 2000 Sep 26;97(20):10990-5. doi: 10.1073/pnas.180329197. Proc Natl Acad Sci U S A. 2000. PMID: 10984506 Free PMC article. Clinical Trial.

10

Vinorelbine and estramustine in androgen-independent metastatic prostate cancer: a phase II study.

Smith MR, Kaufman D, Oh W, Guerin K, Seiden M, Makatsoris T, Manola J, Kantoff PW. Smith MR, et al. Cancer. 2000 Oct 15;89(8):1824-8. doi: 10.1002/1097-0142(20001015)89:8<1824::aid-cncr24>3.0.co;2-r. Cancer. 2000. PMID: 11042579 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

527 results

Search Page